{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:05:00Z","timestamp":1771657500259,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.intimp.2021.108027","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T04:48:52Z","timestamp":1627706932000},"page":"108027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"99","author":[{"given":"Ching-Yi","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5702-7747","authenticated-orcid":false,"given":"Chi-Kuei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ming","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2021.108027_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int. J. Antimicrob. Agents."},{"key":"10.1016\/j.intimp.2021.108027_b0010","unstructured":"WHO. https:\/\/covid19.who.int\/?gclid=CjwKCAjwiLGGBhAqEiwAgq3q_qP6pRDB-zQNmYa-dToZ2Gn8JZqK8egOabpr1yEGJzPtC5y6QvBu6hoCAzYQAvD_BwE Accessed on June 18, 2021."},{"key":"10.1016\/j.intimp.2021.108027_b0015","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1056\/NEJMcp2009575","article-title":"Severe Covid-19","volume":"383","author":"Berlin","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.intimp.2021.108027_b0020","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jmii.2020.02.012","article-title":"Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths","volume":"53","author":"Lai","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.intimp.2021.108027_b0025","doi-asserted-by":"crossref","DOI":"10.3390\/v13040628","article-title":"Neutralizing antibody therapeutics for COVID-19","volume":"13","author":"Hurt","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2021.108027_b0030","unstructured":"NIH. https:\/\/www.covid19treatmentguidelines.nih.gov\/about-the-guidelines\/whats-new\/ Accessed on June 18, 2021."},{"key":"10.1016\/j.intimp.2021.108027_b0035","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00011-021-01445-2","article-title":"Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection","volume":"70","author":"Bahari","year":"2021","journal-title":"Inflamm Res."},{"key":"10.1016\/j.intimp.2021.108027_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.598308","article-title":"Repurposing of biologic and targeted synthetic anti-rheumatic drugs in COVID-19 and hyper-Inflammation: a comprehensive review of available and emerging evidence at the peak of the pandemic","volume":"11","author":"Cavalli","year":"2020","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.intimp.2021.108027_b0045","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/00325481.2020.1855921","article-title":"JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy","volume":"133","author":"Satarker","year":"2021","journal-title":"Postgrad Med."},{"key":"10.1016\/j.intimp.2021.108027_b0050","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/eji.202149173","article-title":"Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection","volume":"51","author":"Solimani","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2021.108027_b0055","article-title":"Ruxolitinib for severe COVID-19-related hyperinflammation in nonresponders to steroids","volume":"1\u20137","author":"Sarmiento","year":"2021","journal-title":"Acta Haematol."},{"key":"10.1016\/j.intimp.2021.108027_b0060","doi-asserted-by":"crossref","unstructured":"J.A. Sparks, Z.S. Wallace, A.M. Seet, M.A. Gianfrancesco, Z. Izadi, K.L. Hyrich, et al., Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry, Ann Rheum Dis. 2021 May 28;annrheumdis-2021-220418. doi: 10.1136\/annrheumdis-2021-220418.","DOI":"10.1136\/annrheumdis-2021-220418"},{"key":"10.1016\/j.intimp.2021.108027_b0065","doi-asserted-by":"crossref","first-page":"94","DOI":"10.14740\/jmc3629","article-title":"A novel report on the compassionate use of baricitinib in treating a pediatric patient with severe symptoms of COVID-19 infection","volume":"12","author":"Atemnkeng","year":"2021","journal-title":"J Med Cases."},{"issue":"3","key":"10.1016\/j.intimp.2021.108027_b0070","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.mayocpiqo.2021.03.007","article-title":"Anti-inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American cohort","volume":"5","author":"Hayek","year":"2021","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes."},{"key":"10.1016\/j.intimp.2021.108027_b0075","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1515\/med-2021-0010","article-title":"Additional baricitinib loading dose improves clinical outcome in COVID-19","volume":"16","author":"Hasan","year":"2021","journal-title":"Open Med. (Wars)"},{"key":"10.1016\/j.intimp.2021.108027_b0080","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s41375-020-01018-y","article-title":"Compassionate use of JAK1\/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study","volume":"35","author":"Vannucchi","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2021.108027_b0085","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/rheumatology\/keaa587","article-title":"Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study","volume":"60","author":"Rodriguez-Garcia","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2021.108027_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102039","article-title":"Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19","volume":"69","author":"Maslennikov","year":"2021","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2021.108027_b0095","article-title":"JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis","volume":"1\u20135","author":"Chen","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2021.108027_b0100","article-title":"The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis","volume":"11","author":"Wijaya","year":"2021","journal-title":"Clin. Epidemiol. Glob Health."},{"key":"10.1016\/j.intimp.2021.108027_b0105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2021.108027_b0110","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.intimp.2021.108027_b0115","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with Covid-19 pneumonia","author":"Guimar\u00e3es","year":"2021","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.intimp.2021.108027_b0120","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement","volume":"134","author":"Page","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.intimp.2021.108027_b0125","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2021.108027_b0130","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2021.108027_b0135","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.tips.2020.06.007","article-title":"Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19","volume":"41","author":"Luo","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.intimp.2021.108027_b0140","article-title":"Cytokine signature induced by SARS-CoV-2 spike protein in a mouse model","volume":"11","author":"Gu","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.108027_b0145","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.3389\/fimmu.2020.01648","article-title":"Cytokine storm in COVID-19-immunopathological mechanisms, clinical considerations, and therapeutic approaches: The REPROGRAM consortium position paper","volume":"11","author":"Bhaskar","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.108027_b0150","article-title":"SARS-CoV-2 Infection induces psoriatic arthritis flares and enthesis resident plasmacytoid dendritic cell type-1 interferon inhibition by JAK antagonism offer novel spondyloarthritis pathogenesis insights","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.108027_b0155","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2021.108027_b0160","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012697","article-title":"Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients","volume":"12","author":"Stebbing","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.intimp.2021.108027_b0165","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jmii.2020.03.005","article-title":"TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib","volume":"53","author":"Wu","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.intimp.2021.108027_b0170","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2021.108027_b0175","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.mayocp.2020.01.039","article-title":"Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis","volume":"95","author":"Wang","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.intimp.2021.108027_b0180","article-title":"The risk of infections associated with JAK inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis","author":"Alves","year":"2021","journal-title":"J. Clin. Rheumatol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921006639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921006639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T20:15:08Z","timestamp":1730837708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921006639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":36,"alternative-id":["S1567576921006639"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108027","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108027"}}